文献速递慢阻肺

恩塞芬特林在中国COPD患者中的疗效与安全性:ENHANCE-CHINA随机临床试验

Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial.
PubMed 文献 · Chest · 2026-03-25

ENHANCE-CHINA是一项III期多中心随机双盲安慰剂对照试验,纳入525例中重度症状性COPD中国患者,按5:3随机接受恩塞芬特林或安慰剂治疗24周。结果显示恩塞芬特林显著改善FEV1曲线下面积(0-12小时),较安慰剂提高110 mL(95%CI 69-151 mL,P<.0001),并改善呼吸困难、症状和生活质量评分,不良事件发生率与安慰剂相似。

要点

  • 恩塞芬特林较安慰剂显著改善FEV1 AUC0-12h达110 mL(95%CI 69-151 mL,P<.0001)。
  • 肺功能改善在有无维持治疗及中重度COPD亚组中一致。
  • 不良事件发生率与安慰剂相似,安全性可接受。

核心结论

  • 恩塞芬特林可显著改善中国COPD患者的肺功能,并在症状和生活质量方面显示疗效获益。

研究设计与样本

  • III期、多中心、随机、双盲、安慰剂对照试验,2023年3月至2025年3月进行。
  • 纳入中重度症状性COPD患者,按5:3随机分配至恩塞芬特林组或安慰剂组,治疗24周。
  • 共525例纳入分析,45.9%接受伴随维持治疗。

主要发现

  • 恩塞芬特林较安慰剂显著改善FEV1 AUC0-12h(110 mL;95%CI 69-151 mL;P<.0001)。
  • 肺功能改善在有无维持治疗及中重度COPD亚组中一致。
  • 恩塞芬特林显著改善过渡期呼吸困难指数评分,并改善 Evaluating Respiratory Symptoms 和 St. George's Respiratory Questionnaire 评分。
  • 恩塞芬特林有降低中重度急性加重率的趋势,并延长首次急性加重时间。
  • 恩塞芬特林组与安慰剂组不良事件发生率相似。

临床怎么用

  • 对于中重度症状性COPD中国患者,可考虑恩塞芬特林雾化治疗以改善肺功能、呼吸困难和健康相关生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ensifentrine, a novel phosphodiesterase 3/4 inhibitor, was shown to significantly improve lung function and reduced COPD exacerbations in previous trials in Western populations. However, efficacy and safety data on its use in Chinese participants with COPD remain limited. RESEARCH QUESTION: Is nebulized ensifentrine effective and safe compared with placebo for the treatment of COPD in Chinese participants? STUDY DESIGN AND METHODS: A phase III, multicenter, randomized, double-anonymized, placebo-controlled trial was conducted between March 2023 and March 2025. The study enrolled participants with moderate to severe symptomatic COPD randomized to the ensifentrine group or the placebo group (5:3) over 24 weeks. Participants were stratified according to maintenance therapy and smoking status. The primary end point was lung function improvement measured by FEV1 area under the curve at 0 to 12 hours. Other end points included quality of life, symptoms, and exacerbations. RESULTS: Overall, 525 participants were included in the analysis, with 45.9% receiving concomitant maintenance therapy. Ensifentrine significantly improved average FEV1 area under the curve at 0 to 12 hours vs placebo (110 mL; 95% CI, 69-151 mL; P < .0001). Lung function improvement was consistent across clinically relevant subgroups, including participants with and without maintenance therapy, as well as participants with moderate and severe COPD. Ensifentrine significantly improved Transition Dyspnea Index score and showed improvements in Evaluating Respiratory Symptoms and St. George's Respiratory Questionnaire scores vs placebo. Ensifentrine treatment tended to reduce the rate of moderate to severe exacerbations and increased the time to first exacerbation. Adverse event rates were similar between the ensifentrine and placebo groups. INTERPRETATION: Ensifentrine was shown to significantly improve lung function and showed efficacy benefits in symptoms and quality of life improvement in Chinese individuals with COPD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT05743075; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Zhou, Chen, Wang, et al. Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial. Chest. 2026. PMID: 41895581. doi:10.1016/j.chest.2026.02.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。